Effect of Rituximab on Immune Function in Pediatric B-cell Non-Hodgkin Lymphoma

Objective: To investigate the effect of rituximab on the immune function of pediatric B-cell non-Hodgkin lymphoma. Methods: According to different treatment methods, 25 children with B-cell non-Hodgkin lymphoma collected from January 2021 to December 2023 were divided into a control group (CHOP chemotherapy, n = 13 cases) and an observation group (CHOP chemotherapy combined with rituximab, n = 12 patients). The incidence of adverse events, clinical efficacy, and immune function of the two groups were observed. Results: Before the treatment, there was no difference between the two groups (P > 0.05); before the treatment, the two groups were different, and the CD3 + and CD4 + levels of the observation group were higher than the control group, and the CD8 + level was lower than the control group (P < 0.05); the total response rate was higher than that of the observation group, and the incidence of adverse events was lower than the control group (P < 0.05). Conclusion: Treatment with rituximab in pediatric B-cell non-Hodgkin lymphoma can effectively improve the immune function of pediatric children, with significant clinical efficacy and a low incidence of adverse events during treatment.